You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
|
|---|---|
| Published in |
Investigational New Drugs, June 2010
|
| DOI | 10.1007/s10637-010-9458-7 |
| Pubmed ID | |
| Authors |
Romain Coriat, Stanislas Ropert, Olivier Mir, Bertrand Billemont, Stanislas Chaussade, Pierre-Philippe Massault, Benoit Blanchet, Olivier Vignaux, François Goldwasser |
| Abstract |
Recently, pneumatosis intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on pneumatosis intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to pneumatosis intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that pneumatosis intestinalis is a probable class-effect of anti-VEGF agents. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| New Zealand | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 16% |
| Researcher | 3 | 12% |
| Librarian | 1 | 4% |
| Student > Bachelor | 1 | 4% |
| Other | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 13 | 52% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 32% |
| Agricultural and Biological Sciences | 2 | 8% |
| Economics, Econometrics and Finance | 1 | 4% |
| Social Sciences | 1 | 4% |
| Sports and Recreations | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 12 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 April 2012.
All research outputs
#6,911,735
of 22,663,969 outputs
Outputs from Investigational New Drugs
#288
of 1,164 outputs
Outputs of similar age
#31,998
of 95,929 outputs
Outputs of similar age from Investigational New Drugs
#9
of 14 outputs
Altmetric has tracked 22,663,969 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,164 research outputs from this source. They receive a mean Attention Score of 4.7. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,929 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.